GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Science, American Association for the Advancement of Science (AAAS), Vol. 378, No. 6615 ( 2022-10-07)
    Abstract: Investment in Africa over the past year with regard to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequencing has led to a massive increase in the number of sequences, which, to date, exceeds 100,000 sequences generated to track the pandemic on the continent. These sequences have profoundly affected how public health officials in Africa have navigated the COVID-19 pandemic. RATIONALE We demonstrate how the first 100,000 SARS-CoV-2 sequences from Africa have helped monitor the epidemic on the continent, how genomic surveillance expanded over the course of the pandemic, and how we adapted our sequencing methods to deal with an evolving virus. Finally, we also examine how viral lineages have spread across the continent in a phylogeographic framework to gain insights into the underlying temporal and spatial transmission dynamics for several variants of concern (VOCs). RESULTS Our results indicate that the number of countries in Africa that can sequence the virus within their own borders is growing and that this is coupled with a shorter turnaround time from the time of sampling to sequence submission. Ongoing evolution necessitated the continual updating of primer sets, and, as a result, eight primer sets were designed in tandem with viral evolution and used to ensure effective sequencing of the virus. The pandemic unfolded through multiple waves of infection that were each driven by distinct genetic lineages, with B.1-like ancestral strains associated with the first pandemic wave of infections in 2020. Successive waves on the continent were fueled by different VOCs, with Alpha and Beta cocirculating in distinct spatial patterns during the second wave and Delta and Omicron affecting the whole continent during the third and fourth waves, respectively. Phylogeographic reconstruction points toward distinct differences in viral importation and exportation patterns associated with the Alpha, Beta, Delta, and Omicron variants and subvariants, when considering both Africa versus the rest of the world and viral dissemination within the continent. Our epidemiological and phylogenetic inferences therefore underscore the heterogeneous nature of the pandemic on the continent and highlight key insights and challenges, for instance, recognizing the limitations of low testing proportions. We also highlight the early warning capacity that genomic surveillance in Africa has had for the rest of the world with the detection of new lineages and variants, the most recent being the characterization of various Omicron subvariants. CONCLUSION Sustained investment for diagnostics and genomic surveillance in Africa is needed as the virus continues to evolve. This is important not only to help combat SARS-CoV-2 on the continent but also because it can be used as a platform to help address the many emerging and reemerging infectious disease threats in Africa. In particular, capacity building for local sequencing within countries or within the continent should be prioritized because this is generally associated with shorter turnaround times, providing the most benefit to local public health authorities tasked with pandemic response and mitigation and allowing for the fastest reaction to localized outbreaks. These investments are crucial for pandemic preparedness and response and will serve the health of the continent well into the 21st century. Expanse of SARS-CoV-2 sequencing capacity in Africa. ( A ) African countries (shaded in gray) and institutions (red circles) with on-site sequencing facilities that are capable of producing SARS-CoV-2 whole genomes locally. ( B ) The number of SARS-CoV-2 genomes produced per country and the proportion of those genomes that were produced locally, regionally within Africa, or abroad. ( C ) Decreased turnaround time of sequencing output in Africa to an almost real-time release of genomic data.
    Type of Medium: Online Resource
    ISSN: 0036-8075 , 1095-9203
    RVK:
    RVK:
    Language: English
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date: 2022
    detail.hit.zdb_id: 128410-1
    detail.hit.zdb_id: 2066996-3
    detail.hit.zdb_id: 2060783-0
    SSG: 11
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Pediatric Blood & Cancer, Wiley, Vol. 69, No. 8 ( 2022-08)
    Abstract: The International Society of Paediatric Oncology‐Paediatric Oncology in Developing Countries (SIOP‐PODC) group recommended graduated‐intensity retinoblastoma treatment for children in low‐ and middle‐income countries with limited local resources. Aim The aim was to improve outcome of children with retinoblastoma by means of a treatment protocol for low‐income settings as recommended by the SIOP‐PODC recommendation in Cameroon. Methods Children diagnosed with retinoblastoma between 2012 and 2016 were treated in two Baptist Mission hospitals in Cameroon, staging according to the International Retinoblastoma Staging System. Treatment included local therapy and combination chemotherapy (vincristine, cyclophosphamide, and doxorubicin) with or without surgery as per SIOP‐PODC guidelines for low‐income countries. Endpoint was survival at 24 months. Kaplan–Meier curves with log‐rank (Mantel–Cox) chi‐square ( χ 2 ) with respective p ‐values were prepared. Results Eighty‐two children were included, of whom 79.3% had unilateral disease. The majority were males (61.0%) with median age 24 months (range 1–112 months; standard deviation [SD] 19). Limited disease was diagnosed in 58.5%, metastatic disease in 35.4%, and unknown stage in 6.1%. Overall survival (OS) was 50.0% at 24 months post diagnosis, but 68.8% for limited disease. Estimated cumulative survival at 24 months was 0.528 (standard error [SE] 0.056). Causes of death included disease progression/relapses (60.5%), neutropenic sepsis (15.9%), unknown causes (18.4%), unrelated infection (2.6%), and death post surgery (2.6%). Stage was significantly associated with OS ( p   〈  .001). Conclusion Stage was the most significant factor for good OS and demonstrated the efficacy and feasibility of the SIOP‐PODC‐proposed management guidelines for retinoblastoma in a lower middle‐income setting.
    Type of Medium: Online Resource
    ISSN: 1545-5009 , 1545-5017
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 2130978-4
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Journal of Tropical Pediatrics, Oxford University Press (OUP), Vol. 67, No. 1 ( 2021-01-29)
    Abstract: Reduced fertility risk is a risk in females treated with a high cumulative cyclophosphamide (CPM) dose. Objectives The objective of this study is to establish the age at menarche, record all pregnancies, calculate age-specific fertility rate (ASFR) in female BL survivors, treated in Cameroon, in the age groups 15–19 and 20–24 years, and association with an increasing cumulative CPM dose. Methods Data collection included personal data and telephone interviews for female survivors, aged ≥12 years with regards to menarche age, their mothers’ menarche age, incidence and outcome of all pregnancies. The cumulative CPM/m2 dose was categorized as low ( & lt;4723 mg/m2), medium (4724–10 635 mg/m/2) or high ( & gt;10 635 mg/m2). Results The median age at first treatment for 113 patients was 8 years (range 3–17 years), with median current age 17 years (range 12–26 years); the median duration of follow-up was 9 years (range 1.2–13.3 years). The median age of patients at menarche (n = 109; 4 unknown) was 14 years (range 10–17 years, SD 1.19) and that of their mothers (n = 68; 45 unknown) 15 years (range 10–17 years, SD 1.53). The median time to first pregnancy following menarche (the fertility time) was 3.04 years (n = 10) with low-dose CPM, 6.09 years with medium-dose CPM (n = 81) and 6.04 years with high-dose CPM (n = 32) (log rank difference p = 0.420). The ASFR in the age group 15–19 years was 82.19 (n = 73) and in the age group 20–24 years was 863.6 (n = 22), with significantly lower ASFR (p  & gt; 0.001) in children treated before the age of 10 years. Conclusion Fertility rates of girls treated for BL with CPM were normal but reduced in patients who commenced treatment before the age of 10 years.
    Type of Medium: Online Resource
    ISSN: 0142-6338 , 1465-3664
    Language: English
    Publisher: Oxford University Press (OUP)
    Publication Date: 2021
    detail.hit.zdb_id: 1497447-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Journal of Molecular Structure, Elsevier BV, Vol. 1305 ( 2024-06), p. 137716-
    Type of Medium: Online Resource
    ISSN: 0022-2860
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2024
    detail.hit.zdb_id: 1491504-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...